+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 76 Actively Recruiting clinical trials

B

Actively Recruiting

Researchers aim to improve understanding and treatment of brain metastases from solid tumors, which currently have limited systemic treatment options. This study focuses on patients with newly diagnosed non-CNS metastatic solid tumors who are at high risk of developing central nervous system CNS metastases. By gathering detailed clinical and biological information, including analyses of circulating tumor DNA ctDNA from cerebrospinal fluid CSF samples, the study seeks to identify new therapeutic targets and develop innovative treatment strategies. The study is organized into three time periods before the first CNS event Part A, at the first CNS diagnosis Part B, and after the first CNS event Part C. Participants will undergo scheduled collections of plasma, serum, CSF samples, and non-CNS metastatic tumor tissue as applicable, along with brain MRI scans at specific intervals depending on their part in the study. Sample collections and imaging are scheduled annually, every few months, or as clinically indicated, aligned with the participants cancer type and study period. Participants will have regular assessments including imaging and biological sample collections to monitor disease progression and tumor biology. Researchers will analyze the epidemiology and biology of CNS metastases over approximately eight years. Study procedures include lumbar punctures for CSF collection, brain MRIs, and collection of tumor tissue when possible. Participants safety and life expectancy are considered, and follow-up will continue throughout the study duration to support data collection and understanding of CNS metastases.

Age: 18Years +All GendersPhase Not Applicable
17 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.

Age: 18Years +All GendersPhase 3
304 locations
G

Actively Recruiting

Researchers are evaluating volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma LA-HNSCC who have not experienced disease progression after completing definitive concurrent chemoradiotherapy cCRT. This Phase III study aims to assess the efficacy and safety of volrustomig as a sequential therapy following standard treatment in this patient group. Participants are randomly assigned to one of two groups one group receives volrustomig, while the other undergoes observation without additional treatment. The study is open-label and conducted globally, with the treatment and observation phases occurring after completion of prior chemoradiotherapy. The study period extends up to approximately 8 years to monitor long-term outcomes. During the study, participants will be regularly assessed for progression-free survival, overall survival, and physical functioning, among other measures. Blood samples will be collected to evaluate the presence of anti-drug antibodies and drug pharmacokinetics. Quality of life questionnaires and safety monitoring for adverse events will also be conducted. Participants may be followed for up to 8 years after starting the study to track these outcomes.

Age: 18Years - 130YearsAll GendersPhase 3
306 locations
L

Actively Recruiting

Researchers are assessing the long-term safety of subcutaneous guselkumab in children with moderate to severe ulcerative colitis, Crohns disease, or juvenile psoriatic arthritis. This Phase 3, open-label study enrolls pediatric participants who previously received guselkumab in one of three primary studies and are considered by their investigator to benefit from continued treatment. The study aims to monitor safety over an extended period to better understand the effects of ongoing guselkumab use in these conditions. Participants who completed dosing in the primary studies will continue guselkumab treatment in this long-term extension study. Dosing schedules include injections every 8 weeks or every 4 weeks, depending on their original study arm and clinical status. Some participants may switch dosing intervals once during the study before unblinding, while others will maintain their initial regimen. The study allows continued access to guselkumab over the long term, with dosing adjustments guided by prior treatment plans and investigator discretion. Throughout the study, participants will be closely monitored for treatment-emergent adverse events for up to 6 years and 9 months. Assessments will include regular evaluations by investigators to ensure safety and adherence. Parents or legal representatives consent for children to participate, with assent obtained from capable participants aged 7 years and older. The study emphasizes long-term safety tracking and maintaining participant well-being during extended guselkumab therapy.

Age: 3Years +All GendersPhase 3
53 locations
P

Actively Recruiting

Researchers are investigating whether a single dose of the immunotherapy drug pembrolizumab given before surgery can help the immune system better fight high-risk melanoma. This study focuses on adults whose melanoma has no visible signs of spreading on scans, aiming to see if early treatment can reduce microscopic cancer cells in the lymph nodes. The study is a Phase 2 clinical trial exploring the potential benefits of this neoadjuvant pre-surgery approach compared to standard post-surgery treatment. Participants receive one intravenous infusion of pembrolizumab six weeks before their scheduled sentinel lymph node biopsy and surgery. After surgery, patients with stage IIB, IIC, or III melanoma continue with standard immunotherapy every six weeks for one year. Those with stage IB or IIA melanoma proceed directly to follow-up care. The treatment plan includes surgery to remove the melanoma and check lymph nodes for cancer spread. During the five-year follow-up period, participants undergo regular physical exams, blood tests, and full-body imaging scans every four months to detect any recurrence of melanoma. Optional quality of life and cognitive function questionnaires are also included. Some participants may have blood tests to measure circulating tumor DNA, which could help predict relapse risk. Safety and treatment effects are closely monitored throughout the study.

Age: 18Years +All GendersPhase 2
1 location
S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
P

Actively Recruiting

The trial investigates the effectiveness and safety of two dosing schedules of pegozafermin compared to a placebo in adults with metabolic dysfunction-associated steatohepatitis MASH who have liver fibrosis stages F2 or F3. This phase 3 study focuses on people aged 18 to 80 years and aims to better understand treatment options for this liver condition. Participants will be randomly assigned to receive one of two pegozafermin regimens or a matching placebo. Both pegozafermin and placebo are given by subcutaneous injection. The study includes a treatment period lasting up to 52 weeks, during which the effects of these regimens on liver fibrosis and steatohepatitis will be assessed. Throughout the study, participants will undergo various evaluations including liver biopsies, blood tests measuring liver enzymes and fibrosis markers, and monitoring for disease progression for up to five years. Researchers will track improvements in liver fibrosis, resolution of steatohepatitis, changes in liver enzyme levels, and fibrosis scores to assess the impact of the treatments.

Age: 18Years - 80YearsAll GendersPhase 3
370 locations
H

Actively Recruiting

Researchers are studying HER3-DXd monotherapy in adults with locally advanced unresectable or metastatic solid tumors that have not responded to prior treatments. This proof-of-concept phase 2 trial includes participants with various cancers such as melanoma, head and neck squamous cell carcinoma, HER2-negative gastric cancer, ovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, prostate cancer, lung cancer, and breast cancer. The study aims to assess how well HER3-DXd works and its safety in these cancers, also exploring the relationship between HER3 protein levels in tumors and treatment response. Participants will receive an intravenous infusion of HER3-DXd at a dose of 5.6 mgkg every three weeks. Treatment continues until disease progression, unacceptable side effects, or withdrawal. The study involves multiple cohorts, each with specific tumor types, and includes monitoring of drug levels in the blood, safety evaluations, and assessments of tumor response over approximately 27 months. During the trial, participants will undergo regular clinical evaluations, imaging scans such as CT or MRI to measure tumor lesions, and laboratory tests. Investigators will assess objective response rates, progression-free survival, overall survival, and treatment-emergent adverse events. Prostate cancer participants will have additional monitoring of prostate-specific antigen PSA levels. The study includes pharmacokinetic analyses of HER3-DXd and long-term follow-up to evaluate treatment effects and safety throughout the participation period.

Age: 18Years +All GendersPhase 2
96 locations
R

Actively Recruiting

Researchers are evaluating saruparib AZD5305 added to standard radiation therapy RT and androgen deprivation therapy ADT compared to placebo in men with high-risk and very high-risk localized or locally advanced prostate cancer who have a BRCA1 or BRCA2 gene mutation. This Phase III randomized, double-blind, placebo-controlled study aims to assess whether saruparib improves metastasis-free survival in this specific group of patients. Participants will be divided into two groups Cohort A includes men with newly diagnosed high-risk prostate cancer or high-risk biochemical recurrence after radical prostatectomy, receiving saruparib or placebo with ADT Cohort B includes men with very high-risk prostate cancer receiving saruparib or placebo combined with ADT plus abiraterone and prednisoloneprednisone. Saruparib and placebo are given orally, alongside standard treatments, and participants will receive the treatment and follow-up according to their assigned cohort. During the study, participants will undergo scans including CT or MRI, bone scans, and PSMA-PET to monitor disease status. Researchers will track survival outcomes, metastasis-free survival up to about 93 months, and overall survival up to 11 years. Blood samples will measure drug concentrations, and safety will be monitored through adverse event reporting. Participants will be followed until the study ends, with ongoing assessments to evaluate treatment effects and safety.

Age: 18Years +MALEPhase 3
346 locations
E

Actively Recruiting

Researchers are evaluating the effects of pitolisant on excessive daytime sleepiness EDS in patients aged 6 years and older with Prader-Willi syndrome. This Phase 3, randomized, double-blind, placebo-controlled global study aims to assess both the efficacy and safety of pitolisant. The study also investigates how pitolisant impacts irritable and disruptive behaviors, hyperphagia, and other behavioral issues such as social withdrawal, stereotypic behavior, hyperactivity, noncompliance, and inappropriate speech. The study includes an up to 45-day screening and baseline period followed by a double-blind treatment phase where participants are randomly assigned to receive either pitolisant tablets or matching placebo tablets once daily in the morning upon waking. This treatment period includes in-person visits on Days 29, 57, and 77. Afterward, participants may enter an optional open-label extension period receiving pitolisant, with visits on Days 113, 260, and 441. Follow-up visits occur 15 and 30 days after the last dose during both treatment periods. Participants will undergo various assessments including patient-reported measures of sleep-related impairment and caregiver and clinical impressions of sleepiness and behavior at baseline and the end of the double-blind phase. Behavioral scales like the Aberrant Behavior Checklist and Hyperphagia Questionnaire are used to evaluate changes. Safety is monitored by tracking adverse events throughout the study. The total duration of participation may extend beyond one year for those joining the extension period.

Age: 6Years +All GendersPhase 3
57 locations

1-10 of 76

1